Ancillary tests for hepatobiliary neoplasms: what we know and what we need to know

被引:2
|
作者
Zhang, Sarah L. [1 ]
Wang, Hanlin L. [2 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA
[2] UCLA, Dept Pathol & Lab Med, David Geffen Sch Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA
关键词
Hepatocellular carci-noma; Hepatocellular adenoma; Bile duct; Cholangiocarcinoma; Metastatic carcinoma; Biomarker; IN-SITU-HYBRIDIZATION; LINDAU GENE-PRODUCT; C-REACTIVE PROTEIN; DIFFERENTIATING HEPATOCELLULAR-CARCINOMA; CELL NUCLEAR ANTIGEN; INTRAHEPATIC CHOLANGIOCARCINOMA; GLUTAMINE-SYNTHETASE; DIAGNOSTIC UTILITY; BILIARY-TRACT; IMMUNOHISTOCHEMICAL MARKERS;
D O I
10.1016/j.humpath.2023.02.001
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Ancillary tests are commonly used in the surgical pathology setting for diagnosing challenging neoplastic diseases of the liver and biliary tract, while histology and clinical correlation remain to be critically important. With continuous discoveries, more and more useful ancillary tests have become available, which can help distinguish between malignant and benign hepatocellular neoplasms, malignant and benign biliary tract entities, and intrahepatic and metastatic carcinomas. This review will focus on existing and emerging biomarkers (such as glutamine synthetase, organic anion transporting polypeptide 1B3, insulin-like growth factor-II mRNA binding protein-3, S100P, SMAD4, enhancer of zeste homolog 2, albumin, hepatocyte nuclear factor-1b, etc.) that can be used for the diagnosis, classification and prognostication of hepatobiliary neoplasms. (c) 2023 The Author(s). Published by Elsevier Inc.
引用
收藏
页码:183 / 200
页数:18
相关论文
共 50 条
  • [31] Endoscopic Ultrasound in the Diagnosis of Extrahepatic Cholangiocarcinoma: What Do We Know in 2023?
    Orzan, Rares Ilie
    Pojoga, Cristina
    Agoston, Renata
    Seicean, Radu
    Seicean, Andrada
    DIAGNOSTICS, 2023, 13 (06)
  • [32] Cognitive Impairment in Parkinson's Disease: What We Know so Far
    Painous, Celia
    Marti, Maria J.
    RESEARCH AND REVIEWS IN PARKINSONISM, 2020, 10 : 7 - 17
  • [33] Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know?
    Previdi, Maria C.
    Carotenuto, Pietro
    Zito, Domenico
    Pandolfo, Rosantony
    Braconi, Chiara
    FUTURE ONCOLOGY, 2017, 13 (05) : 443 - 453
  • [34] LncRNA-ATB in cancers: what do we know so far?
    Feng Tang
    Yadi Xu
    Hongliang Wang
    Erbao Bian
    Bing Zhao
    Molecular Biology Reports, 2020, 47 : 4077 - 4086
  • [35] LncRNA-ATB in cancers: what do we know so far?
    Tang, Feng
    Xu, Yadi
    Wang, Hongliang
    Bian, Erbao
    Zhao, Bing
    MOLECULAR BIOLOGY REPORTS, 2020, 47 (05) : 4077 - 4086
  • [36] Feline comorbidities: What do we really know about feline triaditis?
    Cerna, Petra
    Kilpatrick, Scott
    Gunn-Moore, Danielle A.
    JOURNAL OF FELINE MEDICINE AND SURGERY, 2020, 22 (11) : 1047 - 1067
  • [37] Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?
    Karnes, Jason H.
    PHARMACOGENOMICS, 2018, 19 (18) : 1413 - 1422
  • [38] COVID-19 and liver diseases, what we know so far
    Elnaggar, Mohamed
    Abomhya, Ahmed
    Elkhattib, Ismail
    Dawoud, Nabila
    Doshi, Rajkumar
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (13) : 3969 - 3980
  • [39] Proteomics as a tool to improve novel insights into skin diseases: what we know and where we should be going
    Zheng, Sheng-yuan
    Hu, Xi-min
    Huang, Kun
    Li, Zi-han
    Chen, Qing-ning
    Yang, Rong-hua
    Xiong, Kun
    FRONTIERS IN SURGERY, 2022, 9
  • [40] Clinical utility of coronary artery computed tomography angiography- What we know and What's new?
    Al Rifai, Mahmoud
    Ahmed, Ahmed Ibrahim
    Alahdab, Fares
    Al-Mallah, Mouaz H.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2022, 75 : 12 - 20